ClinicalTrials.gg
CompletedNCT06808646Updated Apr 21, 2026Results posted

A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin

A Phase 1 interventional study of pitavastatin and pitavastatin single dose combined with ceftobiprole in Drug-drug Interaction Study, sponsored by Basilea Pharmaceutica. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical study was to determine the effect of the test drug ceftobiprole (a drug approved for the treatment of bacterial infections) on the elimination of pitavastatin (a drug approved for the treatment of increased levels of cholesterol in blood) from the body. This interaction was investigated by pharmacokinetic (PK) assessments. The clinical study also investigated the safety of ceftobiprole and how well ceftobiprole was tolerated by healthy subjects when it was administered in combination with pitavastatin.

Read the detailed description

This study assessed whether there was an inhibitory effect of ceftobiprole on hepatic organic anion-transporting polypeptide 1B (OATP1B) activity. Pitavastatin was used as an OATP1B substrate in this study. The pharmacokinetics of oral pitavastatin were assessed when administered alone and when administered together with IV ceftobiprole in a study design including 2 treatment periods. In addition, the pharmacodynamic effect of repeated doses of IV ceftobiprole on the diurnal plasma levels of coproporphyrin I (CP-I) was assessed in this study as CP-I is an endogenous biomarker for hepatic OATPB1 activity.

The study duration was up to 38 days.

02

Conditions studied

  • Drug-drug Interaction Study

Keywords

  • Ceftobiprole
  • Pitavastatin
  • OATP1B
  • Coproporphyrin
  • DDI
03

In context

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • : 18.0 to 30.0 kg/m2, inclusive
  • Good physical and mental health
  • Normal renal function ( ≥ 90 mL/min as determined by the Cockcroft-Gault equation)
  • Female participants of were required not be pregnant or lactating and had to agree to use adequate
  • Male subjects, if not surgically sterilized, were required to agree to use adequate contraception
  • All prescribed medication had to be stopped at least 30 days prior to admission to the clinical research center (an exception was made for hormonal contraceptives)
  • All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g., St. John's wort) had to be stopped at least 14 days prior to admission to the clinical research center
  • Ability and willingness to abstain from alcohol from 48 hours (2 days) prior to Screening and admission to the clinical research center
  • Ability and willingness to abstain from methylxanthine-containing beverages or food from 48 hours (2 days) prior to admission to the clinical research center

Main Exclusion Criteria:

  • History of relevant drug and/or food allergies, particularly to antibiotics.
  • Subject received a known potent inhibitor of OATP1B activity within 30 days prior to admission
  • Subject received a potential inducer of OATP1B activity within 30 days prior to admission
  • Subject had a history of seizures
  • Subject had a history of frequent diarrhea
  • Smoking more than 5 cigarettes, 1 cigar, or 1 pipe daily; the use of tobacco products in the 48 hours (2 days) prior to admission
  • History of alcohol abuse or drug addiction within 12 months prior to Screening.
  • Average intake of more than 24 units of alcohol per week
  • Positive drug and/or alcohol screen
  • Donation or loss of more than 450 mL of blood within 60 days prior to the first pitavastatin administration on Day 1 of the current study. Donation or loss of more than 1.5 liters of blood (for male subjects)/more than 1.0 liters of blood (for female subjects) in the 10 months prior to the first pitavastatin administration on Day 1 of the current study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Period 1; pitavastatin 2 mg

    On Day 1, a single oral dose of pitavastatin was administered

    Drug: pitavastatin

  • Experimental
    Period 2; pitavastatin 2 mg combined with ceftobiprole 500 mg

    From Day 4 to Day 7, ceftobiprole (as the prodrug ceftobiprole medocaril sodium) will be administered intravenously (IV) every 8 hours (q8h) for four days. On Day 6, a single oral dose of pitavastatin will be co-administered with ceftobiprole From Day 4 to Day 7, 500 mg ceftobiprole (as the prodrug ceftobiprole medocaril sodium) was administered as a 2-hour IV dose every 8 hours (q8h) under fasted conditions in the morning, and irrespective of timing of food intake further on the day. On Day 6, a single oral dose of 2 mg pitavastatin was co-administered with ceftobiprole 30 minutes prior to the end of the first IV dose of 500 mg ceftobiprole under fasted conditions.

    Drug: pitavastatin single dose combined with ceftobiprole

Interventions

  • Single oral administration

  • Drugpitavastatin single dose combined with ceftobiprole

    Single oral pitavastatin co-administered with IV ceftobiprole

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Pitavastatin

    To assess the pharmacokinetic parameter Cmax in plasma after a single oral dose of pitavastatin administered without and with intravenous (IV) ceftobiprole

    Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose

  2. Area Under the Plasma Concentration-time Curve up to Time (AUC0-t) After Pitavastatin Administration

    To assess the pharmacokinetic parameter AUC0-t after a single oral dose of pitavastatin administered without and with IV ceftobiprole

    Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose

  3. Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) After Pitavastatin Administration

    To assess the pharmacokinetic parameter AUC0-inf after a single oral dose of pitavastatin administered without and with IV ceftobiprole

    Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose

Secondary outcomes

  1. Cmax of Coproporphyrin I (CP-I)

    The pharmacokinetic parameter Cmax for CP-I in plasma was assessed with and without administration of IV ceftobiprole

    Time frame: Sampling on Day 5; pre-dose, 2, 4, 6, 8 h, 16, and 25.5 (Day 6) hours post-dose and corresponding samples on Day -1

  2. Area Under the Plasma Level-time Curve up to Time 25.5 Hours (AUEC0-25.5h) of CP-I in Plasma

    The pharmacokinetic parameter AUEC0-25.5h for CP-I was assessed with and without administration of IV ceftobiprole

    Time frame: Sampling on Day 5; pre-dose, 2, 4, 6, 8 h, 16, and 25.5 (Day 6) hours post-dose and corresponding samples on Day -1

  3. Cmax of Ceftobiprole in Plasma

    To assess the pharmacokinetic parameter Cmax of IV ceftobiprole without and with oral administration of pitavastatin

    Time frame: Sampling on Day 5: pre-dose ,1, 2, 4, 6, 8 h post-dose, on Day 6; pre-dose,1, 2, 4, 6, 8 h post-dose

  4. Area Under the Plasma Concentration-time Curve up to 8 Hours (AUC0-8h) After IV Ceftobiprole

    To assess the pharmacokinetic parameter AUC0-8h after IV ceftobiprole without and with oral administration of pitavastatin

    Time frame: Sampling on Day 5: pre-dose ,1, 2, 4, 6, 8 h post-dose, on Day 6; pre-dose,1, 2, 4, 6, 8 h post-dose

  5. Cmax of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration

    To assess the pharmacokinetic parameter Cmax of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole

    Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose

  6. AUC0-t of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration

    To assess the pharmacokinetic parameter AUC0-t of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole

    Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose

  7. AUC0-inf of of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration

    To assess the pharmacokinetic parameter AUC0-inf of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole

    Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose

  8. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) After Administration of Ceftobiprole Without and With a Single Oral Dose of Pitavastatin

    A treatment-emergent AE (TEAE) was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug

    Time frame: Up to 17 days after first dosing; Pitavastatin Period 1 between first dose on Day1 and before first dose on Day4; ceftobiprole Period 2 between first dose on Day4 and before first dose on Day6; pitavastatin + ceftopibrole Period 2 after first dose on Day6

07

Results

Posted Apr 21, 2026

Participant flow

Twelve (12) subjects were enrolled in the study and completed the study as per protocol. The study was conducted in one research center in the Netherlands.

Participant flow — Overall Study
MilestoneEntire Population of Subjects
Started12
Completed12
Not completed0

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Pitavastatin

To assess the pharmacokinetic parameter Cmax in plasma after a single oral dose of pitavastatin administered without and with intravenous (IV) ceftobiprole

Time frame:
Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Pitavastatin
ng/mLPeriod 1; Pitavastatin 2 mgPeriod 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg
Maximum Observed Plasma Concentration (Cmax) of Pitavastatin42.79 (12.80 to 98.70)33.54 (8.69 to 98.70)
PrimaryArea Under the Plasma Concentration-time Curve up to Time (AUC0-t) After Pitavastatin Administration

To assess the pharmacokinetic parameter AUC0-t after a single oral dose of pitavastatin administered without and with IV ceftobiprole

Time frame:
Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
Reported as:
Geometric mean · ng x h/mL
Area Under the Plasma Concentration-time Curve up to Time (AUC0-t) After Pitavastatin Administration
ng x h/mLPeriod 1; Pitavastatin 2 mgPeriod 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg
Area Under the Plasma Concentration-time Curve up to Time (AUC0-t) After Pitavastatin Administration100.29 (32.7 to 235.0)86.63 (39.1 to 226.5)
PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) After Pitavastatin Administration

To assess the pharmacokinetic parameter AUC0-inf after a single oral dose of pitavastatin administered without and with IV ceftobiprole

Time frame:
Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
Reported as:
Geometric mean · ng x h/mL
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) After Pitavastatin Administration
ng x h/mLPeriod 1; Pitavastatin 2 mgPeriod 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) After Pitavastatin Administration105.42 (35.3 to 241.4)91.59 (42.0 to 232.5)
SecondaryCmax of Coproporphyrin I (CP-I)

The pharmacokinetic parameter Cmax for CP-I in plasma was assessed with and without administration of IV ceftobiprole

Time frame:
Sampling on Day 5; pre-dose, 2, 4, 6, 8 h, 16, and 25.5 (Day 6) hours post-dose and corresponding samples on Day -1
Reported as:
Geometric mean · ng/mL
Cmax of Coproporphyrin I (CP-I)
ng/mLWithout CeftobiproleWith Ceftobiprole
Cmax of Coproporphyrin I (CP-I)0.41 (0.26 to 0.58)0.42 (0.26 to 0.61)
SecondaryArea Under the Plasma Level-time Curve up to Time 25.5 Hours (AUEC0-25.5h) of CP-I in Plasma

The pharmacokinetic parameter AUEC0-25.5h for CP-I was assessed with and without administration of IV ceftobiprole

Time frame:
Sampling on Day 5; pre-dose, 2, 4, 6, 8 h, 16, and 25.5 (Day 6) hours post-dose and corresponding samples on Day -1
Reported as:
Geometric mean · ng x h/mL
Area Under the Plasma Level-time Curve up to Time 25.5 Hours (AUEC0-25.5h) of CP-I in Plasma
ng x h/mLWithout CeftobiproleWith Ceftobiprole
Area Under the Plasma Level-time Curve up to Time 25.5 Hours (AUEC0-25.5h) of CP-I in Plasma9.08 (5.24 to 13.44)9.27 (4.84 to 13.73)
SecondaryCmax of Ceftobiprole in Plasma

To assess the pharmacokinetic parameter Cmax of IV ceftobiprole without and with oral administration of pitavastatin

Time frame:
Sampling on Day 5: pre-dose ,1, 2, 4, 6, 8 h post-dose, on Day 6; pre-dose,1, 2, 4, 6, 8 h post-dose
Reported as:
Geometric mean · ng/mL
Cmax of Ceftobiprole in Plasma
ng/mLDay 5: Ceftobiprole AloneDay 6: Ceftobiprole + Pitavastatin
Cmax of Ceftobiprole in Plasma26361 (21200 to 33600)27423 (22100 to 32600)
SecondaryArea Under the Plasma Concentration-time Curve up to 8 Hours (AUC0-8h) After IV Ceftobiprole

To assess the pharmacokinetic parameter AUC0-8h after IV ceftobiprole without and with oral administration of pitavastatin

Time frame:
Sampling on Day 5: pre-dose ,1, 2, 4, 6, 8 h post-dose, on Day 6; pre-dose,1, 2, 4, 6, 8 h post-dose
Reported as:
Geometric mean · ng x h/mL
Area Under the Plasma Concentration-time Curve up to 8 Hours (AUC0-8h) After IV Ceftobiprole
ng x h/mLDay 5: Ceftobiprole AloneDay 6: Ceftobiprole + Pitavastatin
Area Under the Plasma Concentration-time Curve up to 8 Hours (AUC0-8h) After IV Ceftobiprole104204 (74322 to 136270)105623 (80376 to 140904)
SecondaryCmax of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration

To assess the pharmacokinetic parameter Cmax of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole

Time frame:
Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
Reported as:
Geometric mean · ng/mL
Cmax of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration
ng/mLPeriod 1; Pitavastatin 2 mgPeriod 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg
Cmax of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration15.91 (8.15 to 20.80)14.39 (9.44 to 20.40)
SecondaryAUC0-t of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration

To assess the pharmacokinetic parameter AUC0-t of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole

Time frame:
Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
Reported as:
Geometric mean · ng x h/mL
AUC0-t of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration
ng x h/mLPeriod 1; Pitavastatin 2 mgPeriod 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg
AUC0-t of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration181.18 (94.0 to 304.1)157.11 (107.0 to 229.4)
SecondaryAUC0-inf of of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration

To assess the pharmacokinetic parameter AUC0-inf of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole

Time frame:
Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
Reported as:
Geometric mean · ng x h/mL
AUC0-inf of of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration
ng x h/mLPeriod 1; Pitavastatin 2 mgPeriod 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg
AUC0-inf of of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration196.73 (101.5 to 361.7)171.60 (122.1 to 248.0)
SecondaryNumber of Participants Reporting Treatment-emergent Adverse Events (TEAEs) After Administration of Ceftobiprole Without and With a Single Oral Dose of Pitavastatin

A treatment-emergent AE (TEAE) was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug

Time frame:
Up to 17 days after first dosing; Pitavastatin Period 1 between first dose on Day1 and before first dose on Day4; ceftobiprole Period 2 between first dose on Day4 and before first dose on Day6; pitavastatin + ceftopibrole Period 2 after first dose on Day6
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) After Administration of Ceftobiprole Without and With a Single Oral Dose of Pitavastatin
ParticipantsPitavastatin Period 1Ceftobiprole Period 2Pitavastatin + Ceftobiprole Period 2
Any serious TEAE000
Any non-serious TEAE575
Not any TEAE757

Adverse events

Collected over Up to 17 days after first dosing; Pitavastatin Period 1 between first dose on Day1 and before first dose on Day4; ceftobiprole Period 2 between first dose on Day4 and before first dose on Day6; pitavastatin + ceftopibrole Period 2 after first dose on Day6. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin Period 10/12 (0%)0/12 (0%)5/12 (41.7%)
Ceftobiprole Period 20/12 (0%)0/12 (0%)7/12 (58.3%)
Pitavastatin + Ceftobiprole Period 20/12 (0%)0/12 (0%)5/12 (41.7%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPitavastatin Period 1Ceftobiprole Period 2Pitavastatin + Ceftobiprole Period 2
Catheter site irritationGeneral disorders2/121/123/12
DysgeusiaNervous system disorders2/121/122/12
HeadacheNervous system disorders0/121/122/12
DiarrhoeaGastrointestinal disorders2/122/120/12
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/121/121/12
Abdominal distensionGastrointestinal disorders1/120/120/12
Abdominal painGastrointestinal disorders1/120/120/12
NauseaGastrointestinal disorders0/121/121/12
GastroenteritisInfections and infestations0/120/121/12
Catheter site haematomaGeneral disorders0/120/121/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Population of Subjects
Mean40.4 ± 15.36
Sex: Female, Male
Sex: Female, Male(Participants)Entire Population of Subjects
Female6
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Entire Population of Subjects
White11
Other1
Height (cm)
Height (cm)(cm)Entire Population of Subjects
Mean174.8 ± 7.50
Weight (kg)
Weight (kg)(kg)Entire Population of Subjects
Mean76.67 ± 12.51
BMI
BMI(kg/m2)Entire Population of Subjects
Mean25.00 ± 3.06
08

Study locations

1 site
  • ICON Early Clinical & Bioanalytical Solutions
    Groningen, 9728, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Feb 2025, 1 month.

Results were first posted in Apr 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Feb 5, 2025
StartActual
Jan 17, 2025
Primary completionActual
Feb 25, 2025
CompletionActual
Feb 25, 2025
Results first posted
Apr 21, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06808646
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Feb 5, 2025
Start date
Jan 17, 2025
Primary completion
Feb 25, 2025
Completion
Feb 25, 2025
Results posted
Apr 21, 2026
Last update
Apr 21, 2026

Study contacts

Thomas Kaindl, MD
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion